Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to $1.2 million.

  • Sunshine Biopharma's Change in Accured Expenses rose 31649.89% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 4658.54%. This contributed to the annual value of $4.0 million for FY2024, which is 39203.5% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Change in Accured Expenses is $1.2 million, which was up 31649.89% from -$363693.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Change in Accured Expenses ranged from a high of $2.9 million in Q4 2022 and a low of -$1.0 million during Q2 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $17192.0 (2021), whereas its average is $335674.1.
  • Per our database at Business Quant, Sunshine Biopharma's Change in Accured Expenses skyrocketed by 1026339.35% in 2022 and then crashed by 1099778.84% in 2023.
  • Sunshine Biopharma's Change in Accured Expenses (Quarter) stood at -$28749.0 in 2021, then skyrocketed by 10263.39% to $2.9 million in 2022, then crashed by 126.56% to -$776161.0 in 2023, then surged by 326.07% to $1.8 million in 2024, then plummeted by 30.2% to $1.2 million in 2025.
  • Its Change in Accured Expenses stands at $1.2 million for Q3 2025, versus -$363693.0 for Q2 2025 and -$486009.0 for Q1 2025.